Document is current
Any future updates will be listed below
-
Authors
Tolani, Bhairavi http://orcid.org/0000-0001-9076-866X
Celli, Anna
Yao, Yanmin
Tan, Yong Zi http://orcid.org/0000-0001-6656-6320
Fetter, Richard
Liem, Christina R.
de Smith, Adam J.
Vasanthakumar, Thamiya
Bisignano, Paola
Cotton, Adam D.
Seiple, Ian B. http://orcid.org/0000-0002-8732-1362
Rubinstein, John L. http://orcid.org/0000-0003-0566-2209
Jost, Marco
Weissman, Jonathan S. http://orcid.org/0000-0003-2445-670X
- License Information
-
More Information
Article History
Received: 2 November 2021
Accepted: 3 June 2022
First Online: 25 July 2022
Competing interests
: B.T. is an inventor on the patent filed by UCSF covering these molecules. UCSF has licensed this patent to a start-up biotechnology company. The startup calls 249C ‘RSC-1255’ instead and is running a Phase Ia/1b dose escalation and dose expansion clinical trial for the following indications: Ras mutations; lung cancer; colon cancer; pancreatic cancer; and glioblastoma. It is being run as a multi-center trial across five different sites in the U.S. Recruitment is ongoing (). J.S.W. and M.J. have submitted patent applications related to CRISPR screening. J.S.W. declares outside interest in 5 AM Venture, Amgen, Chroma Medicine, DEM Biosciences, KSQ Therapeutics, Maze Therapeutics, Tenaya Therapeutics, Tessera Therapeutics and Velia Therapeutics. M.J. consults for Maze Therapeutics and Gate Biosciences. All other authors declare no competing interests.
